Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol and ezetimibe crossover study in mucopolysaccharidosis
ChiCTR2500096829Phase 4Not yet recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ambroxol and ezetimibe in Mucopolysaccharidoses (MPS) (2 arms), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Urinary glycosaminoglycan levels, Enzyme activity testing and 11 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ambroxolezetimibe
03
Conditions
Mucopolysaccharidoses (MPS)
Beyond the preview
Go deeper on ChiCTR2500096829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096829.